Table 1.
Species | No. | Origin | Ref. | ELISA | Neutralization titer |
|
---|---|---|---|---|---|---|
VSV–NiV–GFP | Live-NiV | |||||
Human | 1 | NiV outbreak | 1 | + | >1,280 | 15 |
2 | HeV outbreak | 2 | + | 1,280 | 20 | |
3 | + | 1,280 | 20 | |||
4 | Negative control | – | − | <10 | <10 | |
5 | − | <10 | <10 | |||
Fruit bat | 1 | NiV experimental infection | 3 | + | >640 | 240 |
2 | + | >640 | 80 | |||
3 | + | >640 | 160 | |||
4 | Negative control | − | <10 | <10 | ||
Horse | 1 | HeV outbreak | 2 | + | >1,280 | 240 |
2 | + | >1,280 | 240 | |||
3 | + | >1,280 | 480 | |||
4 | + | 160 | 15 | |||
5 | + | >1,280 | 240 | |||
6 | + | >1,280 | 240 | |||
7 | + | >1,280 | 160 | |||
8 | Negative control | – | − | <10 | <10 | |
Cat | 1 | NiV experimental infection | 4 | + | 160 | <10 |
2 | + | >640 | 640 | |||
3 | + | >640 | 640 | |||
4 | Negative control | 4 | − | <10 | <10 | |
Rabbit | 1 | NiV-F DNA immunization | 5 | + | 40,960 | 320 |
2 | + | 164,840 | 480 | |||
3 | NiV-G DNA immunization | 5 | + | 40,960 | 960 | |
4 | + | 40,960 | 1280 | |||
5 | Negative control | 5 | − | <10 | NT | |
6 | − | <10 | NT | |||
7 | − | <10 | NT | |||
8 | − | <10 | NT | |||
Pig | 1 | NiV experimental infection | 6 | + | >1,280 | 60 |
2 | + | >1,280 | 240 | |||
3 | + | >1,280 | 240 | |||
4 | Negative control | 6 | − | <10 | <10 | |
5 | − | <10 | <10 | |||
6 | NiV outbreak in Malaysia | 1 | + | 80 | <20 | |
7 | + | 640 | 60 | |||
8 | + | >1,280 | 240 | |||
9 | + | >1,280 | 80 | |||
10 | + | 640 | 80 | |||
11 | + | 640 | 40 | |||
12 | + | 640 | 80 | |||
13 | + | 640 | 30 | |||
14 | + | 640 | 60 | |||
15 | + | 320 | 20 | |||
16 | + | 160 | 30 | |||
17 | − | <10 | <20 | |||
18 | Japanese field-A αJEV (−) | 7 | − | 5 | NT | |
19 | − | <5 | NT | |||
20 | − | 5 | NT | |||
21 | − | <5 | NT | |||
22 | − | 5 | NT | |||
23 | − | 5 | NT | |||
24 | − | 5 | NT | |||
25 | − | 5 | NT | |||
26 | Japanese field-B αJEV (+) | 7 | − | 40 | <10 | |
27 | − | 40 | <10 | |||
28 | − | 10 | <10 | |||
29 | − | 20 | <10 | |||
30 | JEV experimental infection | 8 | − | <10 | <10 | |
31 | − | <10 | <10 | |||
32 | − | <10 | <10 | |||
33 | − | <10 | <10 | |||
34 | − | <10 | <10 |
(1) Chua et al. (2000), (2) Murray et al. (1995), (3) Middleton et al. (2007), (4) McEachern et al. (2008), (5) see Section 2, (6) Middleton et al. (2002), (7) provided by Dr. T. Takasaki (Department of Virology I, National Institute of Infectious Diseases, Japan, (8) Williams et al. (2001).